Leadership

Chief Executive Officer

Brian Culley

Mr. Culley joined Lineage as CEO in September 2018.  Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

Chief Financial Officer

Brandi Roberts

Ms. Roberts joined Lineage as CFO in January 2019.  Prior to joining Lineage, Ms. Roberts served from August 2017 to January 4, 2019 as Chief Financial Officer at REVA Medical, Inc.  Ms. Roberts previously served as Chief Financial Officer at Mast Therapeutics, Inc., a publicly traded US-based biopharmaceutical company, from January 2013 to April 2017, having served as the Company’s Senior Vice President, Finance from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer.  Ms. Roberts brings more than 23 years of public accounting and finance experience, including 20 years at publicly traded pharmaceutical, medical technology, and life science companies to her position.  Ms. Roberts is a certified public accountant with the State of California and received her B.S. in Business Administration from the University of Arizona and her M.B.A. from the University of San Diego. She also currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers.

Chief Medical Officer

Edward D. Wirth, III, M.D., Ph.D.

Edward D. Wirth, III, M.D., Ph.D., has been our Chief Medical Officer since March 2019. Prior to joining Lineage, he held the roles of Chief Translational Officer and Chief Medical Officer at Asterias Biotherapeutics, Inc. since March 2013. Dr. Wirth previously served as Chief Science Officer at InVivo Therapeutics Corporation from 2011 to 2012. From 2004 to 2011, Dr. Wirth served as Medical Director for Regenerative Medicine at Geron, where he led the world’s first clinical trial of a human embryonic stem cell derived product, GRNOPC1 in patients with subacute spinal cord injuries. Dr. Wirth held academic appointments at Rush-Presbyterian St. Luke’s Medical Center and at the University of Chicago from 2002 to 2004, and was a member of the faculty of the University of Florida from 1996 to 2002. Dr. Wirth received his Ph.D. and M.D. from the University of Florida in 1992 and 1994, respectively.

General Counsel and Corporate Secretary

Chase C. Leavitt

Mr. Leavitt joined Lineage as General Counsel and Corporate Secretary in May 2019. Prior to joining Lineage, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded biotechnology company, from June 2018 to May 2019. From May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel of Switch, Inc., a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014, Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt received a B.S. in Business Administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California.

Chief Executive Officer, Cell Cure Neurosciences

Rami Skaliter, M.Sc., Ph.D.

Rami Skaliter, M.Sc., Ph.D., is the CEO of Cell Cure Neurosciences, a majority-owned (>95%) Israeli subsidiary of BioTime. The site is focused on manufacturing and related research and development activities. Dr. Skaliter was appointed in June 2017. In his last position, Dr. Skaliter worked for ten years as the Chief Operating Officer of Quark Pharmaceuticals, a late-stage pharmaceutical company developing siRNA-based novel therapeutics. Previously, Dr. Skaliter held various corporate and research executive positions at Quark Pharmaceuticals. Dr. Skaliter obtained his B.Sc. in Biology at the Ben-Gurion University and his M.Sc. and Ph.D. in Biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. Between 1993 and 1995, prior to joining Quark, Dr. Skaliter completed a post-doctoral fellowship at Stanford University. Dr. Skaliter serves as a director of Tikcro Technologies Ltd., a public company developing therapeutic antibodies.

Vice President, Business Development

Derek Kelaita

Derek Kelaita joined Lineage Cell Therapeutics as the Vice President, Business Development in August 2019.  Derek brings 20 years of experience with publicly-traded and venture-backed biotechnology companies to Lineage.  He was most recently Vice President of Business Development at ArmaGen from 2013 through early 2019, where he negotiated several early-stage research collaborations and option agreements with pharma partners related to the company’s blood-brain barrier technology as well as a $225M global license agreement with Shire plc (now part of Takeda Pharmaceuticals) for ArmaGen’s lead clinical stage program.  Throughout his career, Derek is responsible for licensing/M&A transactions cumulatively valued at over $1 billion in multiple therapeutic areas including:  Neurology (ArmaGen), Immunotherapy (AnaptysBio), Metabolic/diabetes (Cebix), Dental (Novalar), Infectious disease (Nventa), Oncology (Dendreon) and Cardiovascular disease (Corvas).  He began his career as a Research Associate at the Sanford Burnham Institute in La Jolla, CA.  Derek has a BA in Molecular and Cell Biology from the University of California, Berkeley and an MBA from University of San Diego.

Sr. Vice President, Clinical and Medical Affairs

Gary S. Hogge, D.V.M., M.S. Ph.D.

Gary S. Hogge, D.V.M., M.S. Ph.D., joined Lineage as our Senior Vice President of Clinical and Medical Affairs in February 2018. Dr. Hogge has nearly 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Gary was the Vice President of Medical Affairs at Questcor Pharmaceuticals and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including responsibility for the global clinical development of Tysabri® (natalizumab) in Crohn’s disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene® (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his bachelor’s degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research QIMR in Brisbane, Australia.

Sr. Vice President, Global Head of R&D

François Binette, Ph.D.

François Binette, Ph.D. is Head of Global Development for Lineage. Dr. Binette has over 20 years of experience driving innovation in regenerative medicine therapy development. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel™ for cartilage repair, the first FDA BLA-approved cell therapy product for human use. He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. His systematic approach to demonstrating proof of principle in various indications brought numerous corporate partnership deals helping Biosyntech through a public offering. Dr. Binette then joined the DePuy Franchise of Johnson and Johnson, the second largest orthopedic business worldwide. Dr. Binette led several innovative regenerative medicine combination product development initiatives from bench top to approved clinical trials in US and Europe. Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world’s largest medical device company, developing biologics, active devices and combination products for interventional spine procedures for back pain. Dr Binette received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.